Brian Rini, MD, on Expectations For a Trial Examining MK-1308A Plus Lenvatinib and Pembrolizumab With Other Combinations in ccRCC

Video

Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.

Brian I. Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, spoke with CancerNetwork® at the 2021 European Society for Medical Oncology (ESMO) Congress about his expectations for the results of the upcoming randomized, open-label, phase 3 trial (NCT04736706). The 3-arm study will compare MK-1308A or belzutifan (Welireg) added to lenvatinib (Lenvima) and pembrolizumab (Keytruda) versus the control arm of pembrolizumab plus lenvatinib to treat advanced clear cell renal cell carcinoma in the first-line setting.

Transcription:

The trial’s powered for overall survival and we’ll also look at progression-free survival, response rate, and other typical end points. If positive, it would presumably set a new standard of care and ideally care [for] more patients. We’re now at the point in kidney cancer where we’re curing around 15% to 20% of patients, but that’s obviously still the minority of patients. The hope is, as has been done in other malignancies, by building combination regimens, we can care more patients. That's absolutely the goal.

Reference

Rini BI, Plimack ER, Powles TB, et al. Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol. 2021;32(suppl 5):717TiP. doi:10.1016/annonc/annonc675

Related Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content